The deletion of the gene coding for poly(ADPribose) polymerase-1 (PARP1) or its pharmacological inhibition protects mice against cerebral ischemia and Parkinson’s disease. In sharp contrast, PARP1 inhibitors are in clinical use for the eradication of vulnerable cancer cells. It appears that excessive PARP1 activation is involved in a specific cell death pathway called parthanatos, while inhibition of PARP1 in cancer cells amplifies DNA damage to a lethal level. Hence, PARP1 plays a context-dependent role in cell fate decisions. In addition, it appears that PARP1 plays an ambiguous role in organismal aging.
Cell Stress (CES) emerges as a peer-reviewed publishing platform for high-impact research. CES publishes articles of extraordinary novelty and significance, including research papers and reviews that cover heterogenous topics in the field of cellular pathophysiology.
CES is an open access online journal that thus allows its readership and general public around the world to read, download, store, distribute or print any article free of charge. Long-term archiving and accessibility of all published articles is secured through partnership with different repositories, including PubMed Central.
At the same time, our open access policy ensures fast publication as well as high visibility and broad divulgence of the author’s published research. The financing of this policy is sustained by charging a publication fee/article processing charges (APCs). By pursuing an open access approach and the universal accessibility to scientific knowledge, we support the return to one of the essential values of science: the free exchange of ideas.
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.